Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what gap do you hope SYD985 will fill - Marco Timmers Ph.D. CEO...

Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs - what gap do you hope SYD985 will fill - Marco Timmers Ph.D. CEO...

User Photo
Cancer-News

4 weeks
100 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Marco Timmers, Ph.D., CEO - Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs

https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Up Next Autoplay